More research needed on RA, PsA, axSpA To view or add a comment, sign in Novo Nordisk will present 23 abstracts at ObesityWeek 2025 (4-7 Nov, Atlanta) highlighting its #obesity #pipeline in particular: New results from the Phase 3 OASIS 4 trial of once-daily #oral #semaglutide 25 mg (a #Wegovy in a pill option) exploring #cardiometabolic benefits, physical-function improvements, and comparisons with the #injectable semaglutide formulations
Individual results vary, and a consultation is required to determine the right plan
My ideal client is someone struggling with anxiety, depression, bipolar, schizophrenia, OCD, ADHD or trauma, feeling overwhelmed and seeking relief
"It's appropriate to treat the problems that we now face with drugs, but let's not stop there," Ludwig said